Similar articles for PMID: 20944037

Year	Number of Results
1999	1
2000	8
2001	1
2002	9
2003	2
2004	3
2005	2
2006	1
2007	5
2008	2
2009	3
2010	7
2011	4
2012	8
2013	20
2014	15
2016	1
2017	1
2021	1
2024	0

1

Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.

Smart KA, Lanctôt KL, Paes BA. Smart KA, et al. Can Fam Physician. 2010 Oct;56(10):988-91. Can Fam Physician. 2010. PMID: 20944037 Free PMC article. No abstract available.

2

Early-life wheezing and respiratory syncytial virus prevention.

Lemanske RF Jr. Lemanske RF Jr. N Engl J Med. 2013 May 9;368(19):1839-41. doi: 10.1056/NEJMe1302063. N Engl J Med. 2013. PMID: 23656652 Free PMC article. No abstract available.

3

Palivizumab for the prevention of respiratory syncytial virus infection.

Rogovik AL, Carleton B, Solimano A, Goldman RD. Rogovik AL, et al. Can Fam Physician. 2010 Aug;56(8):769-72. Can Fam Physician. 2010. PMID: 20705882 Free PMC article.

4

Palivizumab and emerging therapies for respiratory syncytial virus.

Hoopes JM, Makari D, Groothuis J. Hoopes JM, et al. Expert Opin Biol Ther. 2012 May;12(5):547-8; author reply 549. doi: 10.1517/14712598.2012.665048. Epub 2012 Feb 21. Expert Opin Biol Ther. 2012. PMID: 22348302 No abstract available.

5

Are we too passive in our attempts to prevent respiratory syncytial virus infection in Northern Canada?

Moraes T. Moraes T. Can Respir J. 2014 May-Jun;21(3):163-4. doi: 10.1155/2014/258504. Can Respir J. 2014. PMID: 24914608 Free PMC article. No abstract available.

6

Palivizumab prophylaxis during respiratory syncytial virus outbreak in the neonatal intensive care unit.

Alan S, Cakır U, Erdeve O, Atasay B, Arsan S. Alan S, et al. Turk J Pediatr. 2013 Mar-Apr;55(2):237-8. Turk J Pediatr. 2013. PMID: 24192692 No abstract available.

7

Palivizumab prophylaxis during respiratory syncytial virus outbreak in neonatal intensive care unit: author's reply.

Oncel MY, Dizdar EA, Dilmen U. Oncel MY, et al. Turk J Pediatr. 2013 Mar-Apr;55(2):239. Turk J Pediatr. 2013. PMID: 24205516 No abstract available.

8

Defining the burden of respiratory syncytial virus infection.

Mejias A, Ramilo O. Mejias A, et al. J Pediatr (Rio J). 2013 Nov-Dec;89(6):517-9. doi: 10.1016/j.jped.2013.08.002. Epub 2013 Sep 19. J Pediatr (Rio J). 2013. PMID: 24055097 Free article. No abstract available.

9

Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?

Elnazir B, Oni O, Hassan T, Greally P, Paes B. Elnazir B, et al. J Paediatr Child Health. 2012 Nov;48(11):1033-8. doi: 10.1111/j.1440-1754.2012.02593.x. J Paediatr Child Health. 2012. PMID: 23126393 Review. No abstract available.

10

Mortality and morbidity among infants at high risk for severe respiratory syncytial virus infection receiving prophylaxis with palivizumab: a systematic literature review and meta-analysis.

Checchia PA, Nalysnyk L, Fernandes AW, Mahadevia PJ, Xu Y, Fahrbach K, Welliver RC Sr. Checchia PA, et al. Pediatr Crit Care Med. 2011 Sep;12(5):580-8. doi: 10.1097/PCC.0b013e3182070990. Pediatr Crit Care Med. 2011. PMID: 21200358 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

89 results

Results by year